40.06 -0.13 (-0.32%)
After hours: 6:49PM EST
|Bid||40.02 x 1100|
|Ask||40.20 x 3100|
|Day's Range||39.97 - 40.41|
|52 Week Range||33.97 - 44.56|
|Beta (5Y Monthly)||0.65|
|PE Ratio (TTM)||14.22|
|Earnings Date||Jan 27, 2020|
|Forward Dividend & Yield||1.52 (3.77%)|
|Ex-Dividend Date||Jan 28, 2020|
|1y Target Est||42.33|
Glaxo's (GSK) BLA for belantamab mafodotin gains the FDA priority review status to treat heavily pre-treated patients with relapsed or refractory multiple myeloma.
Drug companies are not making progress against the spread of antibiotic resistance at a scale and speed great enough to tackle the global health threat posed by superbugs, a key benchmark analysis found on Tuesday. The findings of a second Antimicrobial Resistance (AMR) Benchmark report showed that while a few pharmaceutical companies are expanding their efforts, change is not happening at the scale needed to radically impact the problem. In India, drug resistance exceeds 70% for many widespread bacteria, the AMR report said.
AstraZeneca's (AZN) label expansion application for Lynparza in a prostate cancer indication gets priority review from the FDA. Imfinzi and pipeline candidate, tremelimumab get orphan drug status for liver cancer.
Presidential candidates have the drug industry in their sights, but executives and investors say they are ready.
Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.
Amarin (NASDAQ:AMRN) stock has been choppy for the past year, as the price has made multiple attempts to move above the $23-$24 range. However, this has been a stubborn line of resistance, considering the stock price is currently around $20.Source: Pavel Kapysh / Shutterstock.com Despite this, Amarin stock has still been a pretty good bet over the years. After all, the five-year average return is close to 80%.So, what now? Could there be an opportunity with Amarin stock? Well, I think so.InvestorPlace - Stock Market News, Stock Advice & Trading TipsTo see why, let's get a brief backgrounder on the company. Founded in 1993, Amarin is one of the leaders in leveraging lipid science and polyunsaturated fatty acids to create pharmaceuticals to improve heart health. The main drug is Vascepa, which has posted robust growth. In the latest quarter, revenues hit $112.4 million, up 103% on a year-over-year basis. This has been due to substantial increases in the number of subscribers and higher levels of prescriptions per prescriber. * 10 Cheap Stocks to Buy Under $10 However, the key for Amarin is that it recently gained FDA approval for wider applications for Vascepa. This decision, ironically enough, came on Friday the 13th last month -- but of course, this really should be a very lucky day. Vascepa's DevelopmentThe new indication and label expansion -- which is the result of a decade of research and development -- is for a therapy to reduce "the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥150 mg/dL) and established cardiovascular disease or diabetes mellitus and two or more additional risk factors for cardiovascular disease."Yes, this is kind of medical jargon. But when boiling things down, the new use for Vascepa is a game changer.According to Dr. Deepak Bhatt, an executive director of the Interventional Cardiovascular Programs at Brigham and Women's Hospital Heart and Vascular Center, the treatment "represents one of the most important developments in the prevention and treatment of cardiovascular disease since statins…"The market opportunity is enormous, as there -- on average -- one cardiovascular death occurring every 40 seconds in the U.S. Also, the financial costs of cardiovascular disease events are burdensome at about $500 billion a year -- the most costly in the U.S. The CompetitionThere are a myriad of companies trying to do what Amarin has done; that is, using lipid therapies for cardiovascular disease. But, the science has proven quite complex and challenging.Note that there have been some recent examples of Phase 3 trials that shown disappointing results, such as from AstraZeneca (NYSE:AZN) and Acasti Pharma (NASDAQ:ACST). In fact, since December, ACST has plunged from $2.87 to around $0.80 per share.In fact, Cantor Fitzgerald analyst Louise Chen recently wrote after these companies' failures that "AMRN has been the only company in its class with an outcomes study (REDUCE-IT) that has shown a statistically significant benefit in reducing [cardiovascular] disease. We think the news today underscores our view that AMRN is an interesting asset in a consolidating space." Bottom Line On Amarin StockLast week, Amarin issued revised guidance for 2019. Revenues are now expected to range from $410 million to $425 million, which is at or slightly above the upper end of the prior forecast. The company also noted that beyond 2020, Vascepa's total net revenue "will grow to reach multiple billions of dollars" because "the history of other therapies for chronic conditions suggests that growth builds over multiple years."Given this, the growth story should be robust for quite some time. This should also stir up mergers & acquisitions interest from the mega pharma companies like Pfizer (NYSE:PFE), Merck (NYSE:MRK) and even AZN.Let's face it, they need to fill their pipelines with blockbuster drugs -- and these companies certainly have the resources to pay a premium price for Amarin.Tom Taulli is the author of the book, Artificial Intelligence Basics: A Non-Technical Introduction. Follow him on Twitter at @ttaulli. As of this writing, he did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Cheap Stocks to Buy Under $10 * 5 Retail Stocks Placer.ai Thinks Can Win Big in 2020 * 6 Cheap Stocks to Buy Under $7 The post Why Amarin Stock Is Poised for a Healthy 2020 appeared first on InvestorPlace.
The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.
(Bloomberg) -- U.K. drugmaker GlaxoSmithKline Plc hasn’t made plans to pursue an initial public offering of the consumer-health company it set up with Pfizer Inc. last year, a top executive said, distancing himself from remarks made by Pfizer’s chief executive a day earlier.The comments could expose a lack of communication between the two partners. Pfizer’s Chief Executive Officer Albert Bourla yesterday said he expected Glaxo to pursue an IPO in three to four years.“This is the time that we will be able to exit from this partnership, and I’m sure that this business will have a fantastic IPO,” Bourla said at the J.P. Morgan Healthcare Conference in San Francisco.An IPO isn’t the only option, said David Redfern, Glaxo’s chief strategy officer, in an interview at the meeting. Glaxo said at the time of the deal that it would separate and list the company within three to five years.“Actually we haven’t decided anything,” Redfern said Wednesday. “When we announced the deal, we said we expect it to separate within three years, but actually up to five years. And it’s entirely our decision.”Both Glaxo, the majority owner, and Pfizer, which has about a third of the business, are looking to focus on drug development. Recent shifts in the health-care business and in the broader economy have challenged a model in which drugmakers control every corner of home medicine cabinets.Redfern said the consumer business needed to focus on integration and growing sales, not a spinoff or IPO.“We don’t want it too distracted right now thinking about capital markets,” he said. “Whether it’s an IPO or just a straight spin, all options are on the table. We’ve literally had no discussion” with Pfizer on that topic.With annual sales of about $13 billion, the consumer venture has brought under one roof Advil painkillers, Tums stomach tablets, Sensodyne toothpaste and Nicorette gum.The world’s biggest supplier of over-the-counter medicines will be one of the industry’s only standalones, facing off with companies integrated into larger entities such as Johnson & Johnson, Bayer AG and Procter & Gamble Co.\--With assistance from Mark Schoifet.To contact the reporter on this story: Riley Griffin in New York at email@example.comTo contact the editor responsible for this story: Drew Armstrong at firstname.lastname@example.orgFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Yahoo Finance Editor-in-Chief Andy Serwer sits down with Chairman of the Children’s Health Defense, and President of the Waterkeeper Alliance, Robert F. Kennedy, Jr.
Dixon Boardman, a veteran of the hedge fund industry, is launching a biotech-themed fund, trying to cash on in a wave of investor interest in one of the best performing segments of the US stock market. The New York-based fund manager, who set up Optima Fund Management in 1988 when the industry was in its infancy, plans to launch the fund to invest in a basket of five biotechnology-focused hedge funds, some of which are closed to new investors. The launch comes after the S&P biotech sector doubled since February 2016.
DOW UPDATE Shares of UnitedHealth and Pfizer are posting positive momentum Wednesday morning, sending the Dow Jones Industrial Average into positive territory. The Dow (DJIA) is trading 153 points, or 0.
DOW UPDATE Shares of UnitedHealth and Pfizer are posting positive growth Wednesday morning, propelling the Dow Jones Industrial Average into positive territory. Shares of UnitedHealth (UNH) and Pfizer (PFE) are contributing to the index's intraday rally, as the Dow (DJIA) is trading 78 points, or 0.
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
(Bloomberg) -- Pfizer Inc. is planning an initial public offering of its consumer-health joint venture with GlaxoSmithKline Plc in three to four years as the two drugmakers turn back toward the lab.Pfizer Chief Executive Officer Albert Bourla discussed the time frame for the IPO at the J.P. Morgan Healthcare Conference in San Francisco on Tuesday. The plan provides New York-based Pfizer with a clear exit strategy, he said.The world’s biggest supplier of over-the-counter medicines will be one of the industry’s only standalones, facing off with companies integrated into larger entities such as Johnson & Johnson, Bayer AG and Procter & Gamble Co.With annual sales of about $13 billion, it brings under one roof Advil painkillers, Tums stomach tablets, Sensodyne toothpaste and Nicorette gum.Both Glaxo, the majority owner, and Pfizer, which has about a third of the business, are looking to focus on drug development. Recent shifts in the health-care business and in the broader economy have challenged a model in which drugmakers control every corner of home medicine cabinets.Big pharma companies are increasingly focused on developing high-priced new medicines that draw on cutting-edge research in genetics and other fields. At the same time, the cost of researching new cures is climbing even as insurers and governments demand lower prices.On the consumer-health front, intense price competition online from the likes of Amazon as well as own-brand store products have dented margins in the U.S. and parts of Europe.When the deal was announced, Glaxo said it expected a listing within three years of its close, which took place last August.Glaxo shares rose less than 1% to 1,815 pence in London trading. (Updates with industry context in third and fourth paragraphs)To contact the reporter on this story: Mark Schoifet in New York at email@example.comTo contact the editors responsible for this story: Drew Armstrong at firstname.lastname@example.org, Marthe FourcadeFor more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2020 Bloomberg L.P.
Considering that some of the banking industry's marquee names reported earnings today, it was a mostly sluggish Tuesday as stocks waned near all-time highs even amid some good vibes on the trade front.Source: Provided by Finviz * The S&P 500 inched lower by 0.15% * The Dow Jones Industrial Average gained 0.11% * The Nasdaq Composite fell a modest 0.24% after hitting an all-time on Monday * After reporting fourth-quarter earnings before the bell, JPMorgan Chase (NYSE:JPM) was the Dow's best-in-class name today, adding 1.17%.As noted yesterday, the U.S. and China are scheduled to sign Phase I of a trade agreement tomorrow, but today, the White House said tariffs already in place on Chinese imports will remain in place until after the November elections.The package to be inked on Wednesday "will reportedly commit China to buying some $200 billion of U.S. goods, as well as respecting intellectual property rights and not manipulating its currency," according to Bloomberg.InvestorPlace - Stock Market News, Stock Advice & Trading TipsGeopolitical observers see the trade deal as a win-win for both sides with Chinese President Xi Jinping emerging from the flap with a better of understanding on how to work with President Trump. Whether that facilitates a move forward on more advanced trade talks remains to be seen, but that is something Trump has previously mentioned and it's likely he'd want to use trade successes with China to his benefit on the campaign trail later this year. * 7 Semiconductor Stocks to Buy for Your Inner Geek Amid all the trade conjecture, 18 of 30 Dow stocks were higher in late trading. Crushing EstimatesAs noted above, JPMorgan Chase, the largest U.S. money center bank, was the Dow's top performer today after it reported fourth-quarter results that easily topped analysts' estimates. For the quarter ending Dec. 31, JPM said it earned $2.57 a share on revenue of $29.2 billion. Wall Street expected earnings of $2.36 on revenue of $27.9 billion."While we face a continued high level of complex geopolitical issues, global growth stabilized, albeit at a lower level, and resolution of some trade issues helped support client and market activity towards the end of the year," said JPM CEO Jamie Dimon in a statement.JPM's fourth-quarter ebullience was well diversified as it retains its perch as the top global investment banker in the quarter while seeing expansion in its consumer businesses as well. The results were also boosted by an impressive 86% surge in fixed income trading. Pfizer Gets TechyPfizer (NYSE:PFE) was one of the Dow's laggards last year and there is relevant debate about just how much investors should expect out of the pharmaceuticals giant this year, but the stock gained 1.56% today. The company reached a deal with Insilico Medicine to use that company's technology in high-tech fashion to identify new therapeutics.Pfizer will "utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases," according to a statement. Disney Doing It AgainDisney (NYSE:DIS) gained 0.92% today, ranking in the upper tier of Dow stocks after Sensor Tower said in a report out earlier Tuesday that the Disney + streaming service has been downloaded over 41 million times from the App Store and Google Play and that the Disney service is getting favorable customer reviews.Remember, Disney + is just over two months old and this point confirms the company is going to be a major streaming player. Really SurprisingSomehow, some way, Boeing (NYSE:BA) closed higher today despite some discouraging news flow. Thanks to the ongoing controversy with the 737 MAX jet, the company has ceded the crown of top deliverer of planes in the world to rival Airbus. * 7 Energy Stocks to Buy on the Resurgence of the Oil Boom The company pushed back the return to air date for the plane to June and is reportedly offering substantial discounts on the jet to entice buyers.Add to all that, Moody's Investors Service said late Monday it's putting Boeing's corporate credit rating, currently A3, on review for a possible downgrade. Heightening those concerns is the fact that Moody's lowered its rating on Boeing supplier Spirit AeroSystems (NYSE:SPR). Bottom Line on the Dow Jones TodayIn a vacuum, Tuesday obviously wasn't a good day nor was it an alarmingly bad day for stocks. With fourth-quarter earnings season here and slated to get much busier over the next few days and couple of weeks, the issue at hand is whether S&P 500 companies can deliver results and guidance that merit some of the high multiples some stocks currently sport.The fourth-quarter bar shouldn't be hard to clear, but market participants may have stricter requirements for corporate commentary on 2020.As of this writing, Todd Shriber did not own any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Mid-Cap ETFs to Buy for Next Decade * 8 Quirky ETFs for Not-So-Quirky Profits * 4 Energy Stocks to Power the New Year The post Dow Jones Today: JPMorgan Gives Dow a Lift as Stocks Falter Near Highs appeared first on InvestorPlace.
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Pfizer Inc. New York, January 14, 2020 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Pfizer Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.
DOW UPDATE Shares of JPMorgan Chase and Walgreens Boots are trading higher Tuesday morning, lifting the Dow Jones Industrial Average into positive territory. Shares of JPMorgan Chase (JPM) and Walgreens Boots (WBA) are contributing to the index's intraday rally, as the Dow (DJIA) is trading 73 points (0.
Biogen (BIIB) signs deals with Pfizer to acquire rights to a CNS candidate and develop it as potential therapy to treat certain symptoms/disorders related to Alzheimer's disease and Parkinson's disease.
Insilico Medicine is pleased to announce that it has entered into a research collaboration with Pfizer Inc. (NYSE: PFE) to utilize Insilico's machine learning technology and proprietary Pandomics Discovery Platform with the aim of identifying real-world evidence for potential therapeutic targets implicated in a variety of diseases.